Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nrc Health (NRC) Common Equity (2016 - 2026)

Nrc Health's Common Equity history spans 16 years, with the latest figure at $14.0 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 55.28% to $14.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.0 million, a 55.28% decrease, with the full-year FY2025 number at $14.0 million, down 55.28% from a year prior.
  • Common Equity hit $14.0 million in Q4 2025 for Nrc Health, down from $14.3 million in the prior quarter.
  • Over the last five years, Common Equity for NRC hit a ceiling of $85.3 million in Q4 2021 and a floor of $14.0 million in Q4 2025.
  • Historically, Common Equity has averaged $54.5 million across 5 years, with a median of $62.8 million in 2022.
  • Biggest five-year swings in Common Equity: surged 96.4% in 2021 and later plummeted 58.66% in 2025.
  • Tracing NRC's Common Equity over 5 years: stood at $85.3 million in 2021, then dropped by 15.59% to $72.0 million in 2022, then tumbled by 32.04% to $49.0 million in 2023, then plummeted by 36.1% to $31.3 million in 2024, then tumbled by 55.28% to $14.0 million in 2025.
  • Business Quant data shows Common Equity for NRC at $14.0 million in Q4 2025, $14.3 million in Q3 2025, and $21.3 million in Q2 2025.